PvSTATEM

PvSTATEM: New tools for the control and elimination of P.vivax malaria.

Malaria elimination requires elimination of all malaria species.
Although there been tremendous progress in the development of new interventions for P. falciparum malaria, the goal of malaria elimination cannot be considered achievable unless there is also comparable innovation for interventions specifically targeting P. vivax malaria.

The overall objective is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti – malaria intervention based on Plasmodium vivax serological testing and treatment (PvSeroTAT) with primaquine to prevent the relapse infections responsible to maintaining P. vivax transmission.

Specific objectives are:
– assess the safety and efficacy of community-wide PvSeroTAT with primaquine
– evaluate community acceptability of PvSeroTAT
– innovation of mobile technologies for efficient implementation of PvSeroTAT.

PvSTATEM have developed a diagnostic test to measure antibodies to a selection of P. vivax antigens that identifies individuals who have been recently infected, and thus likely to carry hypnozoites.
These individuals can be targeted for treatment with primaquine to clear hyponzoites and prevent relapse infection. This combination of a novel diagnostic test and primaquine treatment provides a new intervention for malaria control and elimination.

For more info on PV-Statem, please visit:
https://www.pvstatem.eu/

In collaboration with:
1. INSTITUT PASTEUR (IP),
2. ARMAUER HANSEN RESEARCH INSTIUTE (AHRI),
3. Institut Pasteur de Madagascar (IPM),
4. NATIONAL UNIVERSITY OF IRELAND GALWAY (NUI GALWAY),
5. FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS (FIND),
6. MEDEA SRL (MEDEA)